Abstract
Ovarian cancer is a malignancy with poor prognosis and is still the leading cause of death from gynecological malignancies worldwide. A contributing factor to this has been the lack of reliable diagnostic tools for the detection of ovarian cancer. This review focuses on new bloods tests, HE4 and Risk of Malignancy Algorithm (ROMA) that have recently been introduced for risk assessment and management of ovarian cancer patients. Early detection, treatment and management of disease by specialized gynecologic oncologists and new therapeutic advances hold promise for improved outcomes in ovarian cancer patients.
Please view the full content in the pdf above.
